• Camilla died, the eighteen year old from Sestri Levante suffering from thrombosis after being vaccinated

  • Aifa: 66 thousand reports on over 32 million vaccine doses

  • Hope: "The CTS will consider the indications of the ministry and Aifa on AstraZeneca"

  • Vaccines, YES question on AstraZeneca and Johnson & Johnson use

Share

June 11, 2021 AstraZeneca vaccine "recommended for over 60s". This is the opinion on which - as far as we know - there would be a convergence in these hours, which would thus close the question of administering the Anglo-Swedish vaccine to young people.



But on the vaccination of adolescents who have had the first dose with Astrazeneca now remains the crux of the booster, that is the question of which immunizer to use for the second dose in young people already vaccinated with the same vaccine. On this point, various experts say they are in favor of completing the vaccination cycle with AZ anyway. "At this moment, those who have made the first dose with a vaccine should do the second dose with the same vaccine. This is because the experimental tests that led to the approval of these vaccines were made on the administration of two doses for the same vaccine. vaccine and have demonstrated adequate conditions of safety and protection ", said Walter Ricciardi, consultant to the Minister of Health. Along the same lines, the virologist Fabrizio Pregliasco and the infectious disease specialist Massimo Andreoni,according to which the rare adverse events occurred essentially after the first dose and the risk is very low. Confirmation comes from the 5th AIFA Pharmacovigilance Report on Covid Vaccines: the cases of intracranial and atypical venous thrombosis in subjects vaccinated with AZ are in line with what has been observed at European level, i.e. 1 case for every 100,000 first doses administered and mainly in people with less than 60 years. No cases were reported after the second dose.or 1 case in every 100,000 first doses administered and mainly in people under 60 years old. No cases were reported after the second dose.or 1 case in every 100,000 first doses administered and mainly in people under 60 years old. No cases were reported after the second dose. 



Locatelli: opinion on AstraZeneca awaited

"The AstraZeneca vaccine can cause thrombosis phenomena associated with a lowering of platelets. Precisely for this reason there was a recommendation for a preferential use on over 60 years. Now the epidemiological scenario has changed, with vaccination we are in a more favorable phase and a reflection has opened in the CTS and a confrontation with the Aifa. In the next few hours, tomorrow there will probably be an opinion and no one should doubt that warning signs are minimally underestimated with respect to safety profiles ".



This was said in the evening by the coordinator of the Scientific Technical Committee, Franco Locatelli, at 'Porta a porta' on Rai 1, in relation to any decisions to be made after the death of the 18-year-old vaccinated with AstraZeneca.



Vaccine AstraZeneca remains safe. Information on age groups The AstraZeneca vaccine remains safe, reiterates Minister Speranza. But there are many specialists who remember the indication of AIFA to preferentially give it to people over 60 years of age.



 In Genoa, investigation into the death of Camilla, struck by thrombosis after the Oxford vaccine

In the meantime, an investigation has been opened in Genoa on the death of Camilla Canepa, the 18-year-old Genoese girl who died yesterday in the hospital where she had been hospitalized since Sunday after a thrombosis. Camilla on May 25 received a dose of AstraZeneca in the open day for the over 18. The report by Emanuela Pericu